Purpose: Our previous results showed that both gray zone and lower end premutation range (40 -85 repeats) fragile X mental retardation 1 (FMR1) alleles were more common among males with parkinsonism than in the general population. This study aimed to determine whether these alleles have a significant role in the manifestations and pathogenesis of parkinsonian disorders. Methods: Detailed clinical assessment and genetic testing were performed in 14 male carriers of premutation and gray zone FMR1 alleles and in 24 noncarriers identified in a sample of males with parkinsonism. Results: The premutation ϩ gray zone carriers presented with more severe symptoms than disease controls matched for age, diagnosis, disease duration, and treatment. The Parkinson disease (Unified Parkinson's Disease Rating Scale) motor score and the measures of cognitive decline (Mini-Mental State Examination and/or Addenbrooke's Cognitive Examination Final Revised Version A scores) were significantly correlated with the size of the CGG repeat and the (elevated) levels of antisense FMR1 and Cytochrome C1 mRNAs in blood leukocytes. In addition, the carriers showed a significant depletion of the nicotinamide adenine dinucleotide, reduced dehydrogenase subunit 1 mitochondrial gene in whole blood. Conclusion: Small CGG expansion FMR1 alleles (gray zone and lower end premutation) play a significant role in the development of the parkinsonian phenotype, possibly through the cytotoxic effect of elevated sense and/or antisense FMR1 transcripts involving mitochondrial dysfunction and leading to progressive neurodegeneration. Genet Med 2011:13(5):392-399.
F ragile X-associated tremor/ataxia syndrome (FXTAS), OMIM# 300623, first described in 2001, 1 is a progressive late-onset neurodegenerative disorder associated with the premutation (PM) allele of the fragile X mental retardation 1 (FMR1) gene. 2 PM alleles contain small CGG repeat expansions in the promoter region ranging from 55 to 200. 3 Characteristic features of FXTAS are intention tremor, ataxia, and cognitive decline, 1,4 -6 with parkinsonian features occurring in approximately 57% of the affected males. 4, 5 Magnetic resonance imaging changes include white matter lesions of the middle cerebellar peduncles, combined with widespread cerebellar and cerebral white matter T2 hyperintensities. 1,4 -7 Neurohistological changes consist of ubiquitin-positive intranuclear inclusions throughout the brain. 8 The prevalence of PM carriers in the general male population is approximately 1:643, 9 and 40% of these carriers are likely to develop FXTAS as they get older. 4, 6 This has led to screening of patients with late-onset movement disorders for the presence of PM alleles. Although a higher prevalence of these alleles was found among males over 50 with cerebellar ataxia, OMIM# 164400 or multiple system atrophy-cerebellar type, OMIM# 146500, it was not significantly increased in small samples of males with idiopathic Parkinson disease (iPD) or parkinsonism. 10 -13 In a larger study of 776 patients with iPD, three carriers of the PM allele were identified, 14 which is approximately 3-fold higher than the normal population prevalence.
The PM is associated with elevated levels of FMR1 mRNA, 15 and the pathogenesis of FXTAS have been attributed to RNA becoming toxic through a "gain-of-function." 1, 4, 8, 15 Elevation of the FMR1 mRNA to the same "toxic" levels as in PM has also been reported in the carriers of gray zone (GZ) FMR1 alleles, 16 where CGG expansions range from 45 to 54 repeats. 3 It has been suggested that this finding may imply a possible role of these GZ alleles in the origin of the late-onset neurologic involvement already etiologically linked to the PM alleles. 17 However, the role of these GZ alleles in the etiology of FXTAS is not clear because, unlike with PM alleles, the living carriers of GZ alleles do not give rise to, and therefore cannot be accessed through, probands affected with the Fragile X syndrome, OMIM# 300624. Therefore, the prevalence and the phenotype of any GZ-related neurologic involvement cannot be determined in an unbiased manner. The alternative option is to screen those with disorders associated with tremor and/or ataxia for a possible excess of carriers of these alleles.
In contrast to the few earlier screening studies, [12] [13] [14] we have previously reported a significant excess of both PM (10-fold increase) and GZ (2-fold increase) carriers among 228 Australian males diagnosed with typical idiopathic and atypical PD, OMIM# 556500 (subsequently referred together as PD spectrum [PDS] ), compared with the frequency in the general population. 18 In this study, we present the results of in-depth molecular investigations of PM and GZ carriers identified in the PDS sample from this earlier study, 18 comprising the levels of FMR1 mRNA and two mitochondrial measures: the extent of mitochondrial DNA (mtDNA) depletion and the levels of the Cytochrome C1 (CYC1) transcript, a nuclear oxidative-phosphorylation gene expressed during periods of mitochondrial expansion. 19 We have also considered an antisense transcript (AFMR1, also known as FMR4), 20 which has recently been identified within the FMR1 locus. Although its expression has been found to be elevated in the carriers of PM alleles, neither its levels in GZ allele carriers nor the relationship with clinical phenotype have as yet been investigated. The molecular measures have been compared between PDS carriers, PDS noncarriers, and healthy noncarriers and related to measures of severity of parkinsonian manifestations and cognitive decline across the whole range of repeat sizes. The results provide evidence that the size of the CGG repeat expansion, within both the GZ and the lower PM range, is a significant factor contributing to the origin and manifestations of PDS and that toxicity of the elevated FMR1 sense and antisense transcripts in both these allele categories may be linked to mitochondrial dysfunction.
MATERIALS AND METHODS

Subjects
Data collection and analysis were approved by the La Trobe University, St Vincent's Hospital, and Royal Melbourne Hospital Ethics Committees and by the Southern Tasmanian Health and Human Research Ethics and the University Ethics Committees at the Royal Hobart Hospital. Three carriers of PM (55-85 CGG repeats) and 11 carriers of GZ FMR1 alleles (40 -54 CGG repeats) identified by screening in our earlier study of patients with PDS 18 were available, totaling 14 carriers of PM and GZ alleles aged from 54 to 82 years. All these individuals (later referred to as [PM ϩ GZ]/PDS) furnished data on neurologic and neuropsychological scores and CGG repeat size; 12 of these individuals provided data on CYC1 and FMR1 transcript levels and 11 on ASFMR1 transcript levels. As transcriptional activity increases when FMR1 alleles exceed 39 repeats, 16, 18 we have here adopted 40 repeats as the lower boundary of the GZ range. Twenty-four subjects with normal size (Ͻ40 CGGs) FMR1 alleles from the same sample of patients with PDS screened in our previous study 18 and group matched for age and disease duration were selected as major disease controls (referred to as NS/PDS1). Most of these individuals provided neurologic and neuropsychological scores, and four also provided data on FMR1, ASFMR1, and CYC1 transcripts and mtDNA. These two groups, (PM ϩ GZ)/PDS and normal size/PDS1, representing the range of CGG repeat sizes from normal, through GZ, to PM, were used in the analysis of relationships between molecular findings and clinical measures as shown in Table 1 , and Figures 1 and 3 .
A further sample of 20 PDS noncarriers, group matched for age (NS/PDS2), was also included to provide additional molec- ular data for comparative analysis. As this group was not scored either for neurologic involvement or cognitive status, it was not included in the clinical-molecular relationship analysis. Ten of these individuals furnished data on FMR1 and ASFMR1 transcript levels and 13 on CYC1 transcript and nicotinamide adenine dinucleotide, reduced dehydrogenase subunit 1 (ND1) mtDNA depletion levels. Sixteen age-matched healthy controls (HCs) carrying normal size FMR1 alleles provided baseline data for FMR1 and CYC1 transcript levels and 12 of these, also for ASFMR1 mRNA and mtDNA levels. The data from all three PDS samples and HC samples were used to obtain the results shown in Figure 2 . (The summary of data sources and sample sizes for each individual test used in the analyses is given in Table, Supplement Digital Content 1, http://links.lww.com/GIM/A137). All patients with PDS from the carrier and noncarrier groups were receiving treatment with levodopa Ϯ dopaminergic agonists with a daily equivalent dosage of 7.8 (disease controls) and 10.7 (carriers), varying between individuals to achieve an optimal effect. One PM carrier of 56 repeats received deep brain stimulation to the subthalamic nucleus, in addition to the average levodopa dosage. The treatment duration was, on average, 1 year less than disease duration, which was 8.9 years (ranging 1-24 years) in the sample of carriers and 7.9 years (ranging 1-19 years) in the sample of disease controls. All PDS subjects except one PM carrier of 85 CGG repeats had at least mild levodopa responsiveness. All participants were whites, mainly of northern European origin living in Australia.
Laboratory techniques
CGG repeat sizing
Processing of saliva samples and the assessment of the size of the CGG repeat from the extracted DNA (with a precision of Ϯone repeat) were conducted using a fully validated polymerase chain reaction (PCR) amplification assay, as detailed in our previous studies. 21, 22 Blood sample processing Fifteen milliliters of blood was collected in ethylene diaminetetraacetic acid tubes (BD, worldwide) from all participants. DNA was extracted from 7.5 mL of whole blood using a BIO ROBOT M48 DNA Extractor (Qiagen Inc., Hilden, Germany). Peripheral blood mononuclear cells (PBMCs) were isolated from the remaining 7.5 mL of blood using Ficoll gradient separation, according to the manufacturer's instructions (Amersham Pharmacia Biotech, Uppsala, Sweden). Total RNA was extracted and purified from PBMCs using the RNeasy extraction kit, as per the manufacturer's instructions (Qiagen Inc., Hilden, Germany). The samples were stored at Ϫ80°C until further analysis.
mtDNA depletion analysis using real-time PCR
The 7900HT Fast Real-Time PCR machine (Applied Biosystems, Foster City, CA) was used to quantify the mtDNAencoded ND1 gene in DNA from whole blood. In this study, we modified the method originally developed for analysis of muscle and fibroblasts 23 for whole blood, such that ND1 analysis was performed using an absolute real-time PCR standard curve method, 24 normalized to total genomic DNA concentration determined using a NanoDrop ND-1000 Spectrophotometer. The ND1 dynamic linear range was performed on a series of doubling dilutions of a DNA standard (160 -4 ng/L) from whole blood. Previously published sequences were used for primers and for the probe for ND1, 23 which were each used at a concentration of 10 M. All samples were assayed in duplicate 
RNA extractions and reverse transcription real-time PCR
Total RNA was extracted, purified, and reverse transcribed as described previously. 21, 25 The 7900HT Fast Real-Time PCR (Applied Biosystems) was used to quantify FMR1-5Ј, FMR1-3Ј, ASFMR1, GAPDH, B2M, and GUS, using the relative standard curve method. DNase treatment of total RNA was found to significantly affect levels of ASFMR1 and FMR1 (unpublished data) and, therefore, was not used for this study. The target gene and the internal control gene dynamic linear ranges were performed on a series of doubling dilutions of an RNA standard (160 -4 ng/L). A no reverse transcription enzyme control was included for every sample for ASFMR1 (as these assays did not target an exon/exon boundary). The difference between the plus and minus no reverse transcriptase control was considered as the ASFMR1 expression value for each sample. Previously published sequences were used for primers and probes for FMR1-5Ј and GUS 15 ; FMR1-3Ј 26 ; and ASFMR1 (FMR4). 27 FMR1-5Ј, FMR1-3Ј, and ASFMR1 primers were used at a concentration of 18 M and probes at a concentration of 2 M. EIF4A2 and SDHA primer/probe mixes were obtained from PrimerDesign (PerfectProbe ge-PP-12-hu kit) and used at a concentration of 2 M. All the above assays were single plexed, with each sample assayed in duplicate 10 L PCR reactions. The reaction mixes consisted of 5.8 mM MgCl 2 , 1 L Buffer A (Applied Biosystems), 3.35 L RNase-free water, 1.2 mM deoxynucleotide triphosphates, 0.01 units/L of AmpliTaq Gold, 0.5 L of TaqMan probe and 0.5 L forward and 0.5 L reverse primers, and 1 L of the reverse transcription (cDNA) reaction. The annealing temperature for thermal cycling protocol was 60°C for 40 cycles. The samples were quantified in arbitrary units in relationship to the standard curves performed on each plate, standardized to the mean of the three internal control genes (GUS, EIF4A2, and SDHA).
Clinical scores
Neurologic assessments
A standard neurologic assessment was conducted using the Unified Parkinson's Disease Rating Scale (UPDRS) Part IIIMotor Examination. 28 The (videotaped) assessments and scoring of both carrier and disease control samples were conducted by two neurology specialists (E.S. and K.E.K.), with relevant experience of the UPDRS, which has established interrater reliability. 29 They were blind to the CGG results. Further quantitative assessment of tremor was conducted using the windowbased CATSYS 2000 system, Version 1.3.8 (Danish Product Development Ltd., DK-3070 Snekkersten, Denmark), 30, 31 which has been normalized using a sample size of 150 men and women, aged 20 -70 years. 30 The measures considered were (a) postural tremor intensity measured by an accelerometer held like a pen in a horizontal plane approximately 2.5 cm from the umbilicus and (b) simple reaction time (RT), which measures a stimulus-response speed (in seconds) for sound signals given at random within fixed periods.
Neuropsychological measures
Addenbrooke's Cognitive Examination Final Revised Version A (ACE-R) 32 was used to screen for cognitive impairment. The total score (ACE-R full) was a raw score derived from the sum of the five subscores, measuring attention/orientation, memory, fluency, language, and visuospatial cognitive domains. A full Mini-Mental State Examination (MMSE) is embedded within the ACE-R and is particularly useful in the assessment of severity in patients with dementia, OMIM# 127750. 33 Processing speed was measured using the Symbol Digit Modalities Test. 34 The testing was conducted by one trained neuropsychologist (P.S.) who was not aware of the participants' carrier status at the time of assessment.
Statistical analyses
The data were analyzed using STATA statistical software (Version 10.0, StataCorp, College Station, TX) and plotted using the publically available R package. 35 Because of the small sample size and the non-Gaussian distributions, we compared the measures (including age, disease duration, UPDRS motor scores, FMR1 sense and antisense transcripts, CYC1 transcript, and levels of mtDNA) from the sample of carriers with those from disease controls and/or HCs, using the nonparametric Kruskal-Wallis test. Analysis of the relationships between major phenotypic and molecular measures was conducted using robust regression to downweight the effect of outliers. Both Huber weights and Tukey biweight, with the default biweight tuning constant of 7, were applied. We also applied least square estimations to assess the effect of outliers on the regression results.
Although the samples were group matched for age, both measures of dementia (MMSE and ACE-R) were found to be age related and were thus adjusted for age in all the regression analyses involving these two variables. However, there was no significant difference in disease (and thus treatment) duration between PDS carrier and noncarrier samples (P ϭ 0.278), and this trait was not a significant confounder in any analyses conducted in this study.
RESULTS
We first tested the hypothesis that CGG expansion size and possibly the associated molecular changes are significantly related to the severity of parkinsonian manifestations, including the level of cognitive decline. Strong evidence for the effect of CGG repeat size on these manifestations, based on data from 14 (PM ϩ GZ)/PDS subjects and 24 NS/PDS1 controls, was provided by the finding (Fig. 1A) that the UPDRS motor score was significantly elevated in the sample of (PM ϩ GZ)/PDS compared with NS/PDS1 (P Ͻ 0.001) and that this score was also significantly related to CGG repeat size (Fig. 1B) . The CGG expansion size was also significantly correlated with the MMSE score (representing cognitive decline) and with RT assessed by CATSYS (Table 1) . That the severity of neurologic involvement is also affected by other relevant molecular changes arising from small expansion FMR1 alleles is shown by the results of regression analyses that included the levels of both sense and antisense FMR1 transcripts as explanatory measures and several parkinsonian motor measures and cognitive scores as dependent variables (Table 1) . Despite the small sample size, the levels of both these transcripts were significantly elevated in the (PM ϩ GZ)/PDS sample compared with the NS/PDS1&2 samples (Fig.  2, A and B) and showed marginally significant associations with the UPDRS motor score. Notably, although FMR1 transcript levels were not significantly associated with other clinical measures, ASFMR1 levels showed significant correlation with all but one measure (CATSYS-RT).
We initially included CYC1 expression analysis to determine a set of the most stable reference genes for an assessment of the FMR1 mRNA levels from a set described by Vandesompele et al., 36 using the geNorm algorithm. However, unlike any other reference genes included in the relevant kit (PrimerDesign kit PerfectProbe ge-PP-12-hu kit), the CYC1 gene showed differences in expression between the carrier and disease control groups (Fig. 2C) . More specifically, the CYC1 transcript was found to be elevated in the (PM ϩ GZ)/PDS sample relative to HCs, and the levels of this transcript showed a highly significant relationship with the severity of parkinsonian manifestations (UPDRS motor score) and with cognitive decline (ACE-R) ( Table 1 and Fig. 3A) . Notably, CYC1 mRNA was also significantly increased in the NS/PDS1&2 group compared with the HC subjects (two-sided P ϭ 0.021) but to a lesser extent than in the (PM ϩ GZ)/PDS group (two-sided P ϭ 0.01) (Fig. 2B) . The highest levels of CYC1, as well as FMR1 and ASFMR1 transcripts in PBMCs, were found in two carriers with 85 and 170 CGG alleles, respectively (Fig. 2, A-D) . These findings imply, Fig. 1 . Relationship between the UPDRS motor score and CGG expansion size based on data from a sample of carriers of PM and GZ alleles and a sample of disease controls, all identified through screening 228 Australian males affected with PDS. A, Boxplot showing the differences in UPDRS motor score between NS/PDS1 and PM ϩ GZ/PDS samples. B, Scatterplots and regression lines fitted using robust regression of UPDRS motor score on CGG repeat size in the combined sample of PM and GZ carriers and disease controls.
first, that the changes in CYC1 expression as seen in the (PM ϩ GZ)/PDS sample may be relevant to the FMR1 mRNA toxicity, thus contributing to the severity of clinical manifestations of parkinsonism and second, considering that CYC1 expression levels are closely linked to the degree mitochondrial expansion or depletion, 19 that mitochondrial dysfunction might be involved in toxicity of the FMR1 transcripts.
Therefore, as the next step, we assessed the levels of mtDNA in whole blood, where we found significantly reduced levels of ND1 gene mtDNA in the (PM ϩ GZ)/PDS sample compared with both a subset of the NS/PDS1&2 (P ϭ 0.025) and HC (P ϭ 0.019) groups (Fig. 2D) . Despite the small samples sizes, ND1 mtDNA depletion was also significantly related to the number of CGG repeats within the PDS and GZ only category (P ϭ 0.011) (Fig. 3C) and to the rate of cognitive decline as represented by MMSE scores (P Ͻ 0.001) (Fig. 3D) .
The scatterplots in Figure 3 , A-D show that the significant relationships between phenotypic measures and the molecular changes have not been driven by single outliers in small samples but represent a general trend in the data. This has been confirmed using least square estimations, which showed that, if the outliers (numbering between 0 and 4 for individual correlations) were omitted from the analysis, or if there were no outliers (such as for correlations involving the UPDRS), the P values were identical or almost identical to those obtained from the robust regression analysis. If the outliers were left in the analysis, the correlations became insignificant (P Ͼ 0.05) for CATSYS-RT/CGG and ACE-R/ASFMR1 relationships but remained significant for the MMSE relationships with CGG repeat numbers and ASFMR1 transcript levels. Examples of the regression lines using both robust and least square methods are given in Figure 
DISCUSSION
We have shown that the size of FMR1 CGG expansion within the low PM and GZ range affects the severity of parkinsonian manifestations in a sample of carriers of these alleles previously identified within a cohort of subjects diagnosed with PDS, 18 irrespective of age and disease duration. The pattern of the relationships between the CGG repeat size and the severity Fig. 2 . Expression levels of sense (FMR1) and antisense (ASFMR1) transcripts, and a marker of mitochondrial dysfunction (ND1 mtDNA/total DNA) in peripheral blood of PM and GZ carriers (PM ϩ GZ/PDS) compared with both disease control samples (NS/PDS1&2), and healthy controls (HCs). A, FMR1 5Јand 3ЈmRNA levels in PBMCs; B, ASFMR1 mRNA levels in PBMCs; C, CYC1 mRNA levels in PBMCs; and D, mtDNA ND1 levels in whole blood. PM/FXTAS is a PM carrier of 85 CGGs affected with FXTAS; and PM/UN is a PM carrier of 170 CGGs of unknown phenotype. Both these carriers were ascertained through fragile X families and have not been included in global analyses. **P Ͻ 0.05 compared with HCs; and ##P Ͻ 0.05 compared with NS/PDS1&2. of the motor phenotype and cognitive decline across the normal and PM/GZ range suggest an incremental effect of the repeat size. The previously reported significant relationship between cognitive decline and the size of one CGG repeat across the whole range of small expansions and the normal range in a sample of patients with PD 12 is consistent with our findings. These results together support our hypothesis from our earlier study 18 that CGG repeat expansions encompassing both the GZ and the low-end PM range may contribute to phenotypic acceleration or modification of PD by synergizing with mechanisms relevant to its etiology and pathogenesis. Unlike larger alleles within the PM range, the allele sizes within the lower PM range and the GZ range may not be sufficient to produce FXTAS but may predispose the carriers to other conditions such as parkinsonism, where similar pathomechanisms may converge, resulting in increased risk or severity of manifestations of this disorder.
The major objective of this study was to uncover possible mechanisms involved in FMR1 mRNA toxicity and leading to neurodegenerative changes. A novel finding from this study is that the elevated levels of the sense (FMR1) and especially of the antisense (ASFMR1) transcripts also showed an incremental effect on the severity of the parkinsonian phenotype. The unanticipated finding of an effect of CYC1 expression on this phenotype, combined with the observed correlation of CYC1 expression levels with CGG repeat size and with the levels of both FMR1 transcripts, suggested that the effect of CGG expansions on the parkinsonian phenotype might be mediated through mitochondrial dysfunction. This is supported by the finding of significant mtDNA depletion in whole blood in the GZ/PM group compared with either HC or PDS noncarrier samples.
Evidence for mitochondrial dysfunction related to CGG expansions within the PM range has also been recently described in fibroblasts and brain material from patients with FXTAS ascertained through fragile X families. 37 The results from that study are consistent with our findings of relationships between CGG expansion size, FMR1 and ASFMR1 transcript levels, and selected markers of mitochondrial dysfunction, with phenotypic measures. This suggests that the mitochondrial dysfunction related to RNA toxicity in accessible cell types such as fibroblasts and blood leukocytes, which have been used in our study, is likely to be paralleled by mitochondrial dysfunction in brain cells. Our findings, if confirmed in a larger sample, may contribute to a development of convenient molecular markers in blood, including CYC1 expression and mtDNA depletion, as useful predictors of disease severity and/or response to treatment. In our study, we have shown that mitochondrial dysfunction may also be associated with the much more common GZ alleles, thereby contributing to the severity of neurologic manifestations in patients with PDS carrying these alleles.
Another unprecedented finding of our study was that of an elevation of CYC1 levels in patients with PDS compared with HCs, with a further increase in these levels in PDS GZ/PM carriers; a similar pattern was encountered for the ND1 mtDNA depletion. However, the interpretation of this finding is not straightforward. Because of the links of CYC1 with mitochondrial complex III, 38 which is required to maintain functionality of complex I in mammalian mitochondria, 39 the over or underexpression of CYC1 may potentially lead to destabilization of complex I. For example, mutations in the CYC1 gene have been reported to lead to a loss of functional mitochondrial complex III. Both impairment of complex I in substantia nigra and platelets and subsequent oxidative stress have been proposed as major factors in the pathogenesis of PD, 40 and the interaction of this pathway with other potential factors causing oxidative stress has been postulated. 41 In addition to lowered complex I activity in platelet mitochondria of patients with PD, reduction in complex II/III activity (which may be relevant to aberrant CYC1 expression) has also been reported in this disorder. 42 The elevation of CYC1 in PDS noncarriers that we have shown may reflect a specific pathway linked to complex I dysfunction or may be part of a broader cellular response, for example, secondary to loss of mtDNA. Mitochondrial dysfunction can result in up and downregulation of a range of specific nuclear genes, in an integrated stress response or retrograde response that varies in different cell types. 43, 44 The finding that CYC1 is further elevated in carriers raises the possibility that the observed mitochondrial changes in the GZ/PM carriers may interface with the oxidative stress pathway associated with PDS, leading to a more severe phenotype by exacerbating oxidative stress or dysfunction in mitochondrial pathways. This possibility is also suggested by earlier reports of elevated lactate levels in the lateral ventricles in both patients with FXTAS 45 and patients with iPD. 46 At this stage, it is not clear how the suggested mitochondrial dysfunction in carriers of PM/GZ alleles may be linked to the "toxicity" of elevated FMR1 transcript levels, but a deeper understanding of the disease mechanisms associated with these alleles may raise the possibility of treatment. It is possible that some proteins sequestrated through contact with the expanded FMR1 RNA 47 have a physiological function in mitochondria and, through the "gain of function" mechanism previously postulated for alpha-synuclein toxicity, 48 may cause dysfunction of these organelles.
In conclusion, our data, although based on small samples, show that the presence of either GZ or lower end PM alleles contributes significantly to the pathogenesis of parkinsonism, possibly through the cytotoxic effect of elevated FMR1 and/or ASFMR1 mRNA leading to mitochondrial dysfunction. Considering the exceptionally high prevalence of GZ alleles, which are carried by at least 1 in 30 individuals in the general population, 9 larger studies are required to confirm these findings and also to establish whether this factor increases the risk for, and severity of, iPD, or determines a phenotypically overlapping entity within the heterogeneous group of primary parkinsonian disorders. Moreover, the link between the elevated FMR1 transcript and mitochondrial dysfunction, and the relevance of these to neuronal cell death, should be further explored through functional experiments. Furthermore, despite the small sample size, when the evidence presented in this study is considered together with previous findings in PM carriers 37 and our earlier report of a significant association between CYC1 and FMR1 expression in GZ carriers with neurodevelopmental disorders, 21 it suggests that the proposed link between elevated transcription at the FMR1 locus, CGG expansion within GZ/PM range, and mitochondrial dysfunction may extend beyond neurodegenerative disorders.
